MZ0481

MZ0481 is an investigational small‑molecule **dual Bruton tyrosine kinase (BTK) and mucosa‑associated lymphoid tissue lymphoma translocation protein 1 (MALT1) fusion inhibitor** designed to overcome resistance mechanisms in B‑cell malignancies driven by chronic active B‑cell receptor (BCR) signaling. In preclinical models, including Z138 mantle cell lymphoma xenografts, MZ0481 produced marked tumor growth suppression and outperformed comparator agents, supporting the concept that simultaneous BTK and MALT1 inhibition can more effectively shut down BCR and NF‑κB signaling than targeting either node alone.[2] Publicly available data do not yet disclose the company developing MZ0481, its clinical development stage, or specific human indications beyond its positioning for treatment of resistant B‑cell lymphomas.